Tracking Metrics for Regulatory Submission Performance in Multinational Portfolios

Abstract

ABSTRACT

Effective management of regulatory submission performance across multiple jurisdictions directly influences a company’s ability to bring life-saving therapies to patients in a timely manner. This expanded study analyzes key performance indicators—submission timelines, approval rates, and regulatory query frequencies—in the context of multinational portfolios spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East. Drawing on a dataset of 120 regulatory submissions between January 2017 and December 2021, we provide a granular examination of regional disparities and underlying drivers. We describe methodology enhancements, including data validation protocols, sensitivity analyses on outlier timelines, and supplementary subgroup analysis by product type (small molecules versus biologics). Our statistical analysis employs descriptive metrics, one-way ANOVA with effect‐size calculations, chi-square tests augmented by Monte Carlo simulation for sparse cells, and regression modeling to quantify the impact of query frequency and dossier complexity on submission duration. Results reveal that Asia-Pacific and Latin America portfolios face significantly longer review periods—averaging 230 and 240 days, respectively—with query volumes 58–75% higher than those in North America. Subgroup analyses indicate that biologics incur 15–20% longer timelines than small molecules, particularly in emerging markets. Conclusions stress the importance of proactive dossier customization, early engagement with local health authorities, and investment in regulatory intelligence tools. We discuss practical best practices, such as leveraging regulatory liaisons, deploying AI‐driven dossier quality checks, and establishing global cross‐functional governance forums. Scope and limitations address data representativeness, retrospective design constraints, evolving regulatory frameworks post-2021 (e.g., EMA accelerated assessments), and the need for prospective validation. Twenty APA-style references underpin the findings and recommendations.